COLUMBUS, Ohio – Spool-like proteins called histones play a crucial role in packaging the nearly seven feet of DNA found in most human cells. A new study shows that a group of histones that are thought to behave the same way actually are functionally distinct proteins.
The findings by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) indicate that replication-dependent histone isoforms can have distinct cellular functions, and that changes in expression of the various isoforms might play a role in cancer development.
The study is published in the journal Nucleic Acids Research as a Breakthrough Article, placing it among the top 2-3 percent of papers presented by the journal in terms of significance and excellence.
"Replication-dependent histone isoforms have always been thought to be functionally identical, but we show that they have distinct functions, and that altering the levels of these isoforms can influence cell proliferation and tumor development," says principal investigator Mark Parthun, PhD, professor of Molecular and Cellular Biochemistry and a member of the OSUCCC – James Experimental Therapeutics Program.
"These highly novel results provide a new mechanism for the regulation of chromatin structure, Parthun says."
Replication-dependent histones are highly expressed just before the onset of DNA replication during the cell cycle, and they are repressed when DNA replication is completed.
The genes that encode these histones are located in large clusters that can contain dozens of histone genes. "This localization in gene clusters led to the belief that these histones are regulated as a group, and that the multiple genes encoding each histone are functionally equivalent," Parthun says.
However, the proteins encoded by replication-dependent histone genes are not identical. For example, 16 genes encode the replication-dependent histone called H2A. Strikingly, these genes encode 11 distinct protein variations, he notes.
Parthun and his colleagues conducted the study using three bladder-cancer cell lines. Key findings include:
Funding from the NIH/National Cancer Institute (grant CA101956, CA107106) and the Leukemia and Lymphoma Society supported this research.
Other researchers involved in this study were Rajbir Singh, Amir Mortazavi, Kelly H. Telu, Prabakaran Nagarajan, David M. Lucas, Jennifer M. Thomas-Ahner, Steven K. Clinton, John C. Byrd and Michael A. Freitas, The Ohio State University.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.